A Descriptive Review of the Action Mechanisms of Berberine, Quercetin and Silymarin on Insulin Resistance/Hyperinsulinemia and Cardiovascular Prevention
- PMID: 37298967
- PMCID: PMC10254920
- DOI: 10.3390/molecules28114491
A Descriptive Review of the Action Mechanisms of Berberine, Quercetin and Silymarin on Insulin Resistance/Hyperinsulinemia and Cardiovascular Prevention
Abstract
Insulin resistance (IR) and the associated hyperinsulinemia are early pathophysiological changes which, if not well treated, can lead to type 2 diabetes, endothelial dysfunction and cardiovascular disease. While diabetes care is fairly well standardized, the prevention and treatment of IR lacks a single pharmaceutical approach and many lifestyle and dietary interventions have been proposed, including a wide range of food supplements. Among the most interesting and well-known natural remedies, alkaloid berberine and the flavonol quercetin have particular relevance in the literature, while silymarin-the active principle of the Silybum marianum thistle-was traditionally used for lipid metabolism disorders and to sustain liver function. This review describes the major defects of insulin signaling leading to IR and the main properties of the three mentioned natural substances, their molecular targets and synergistic action mechanisms. The actions of berberine, quercetin and silymarin are partially superimposable as remedies against reactive oxygen intermediates generated by a high-lipid diet and by NADPH oxidase, which is triggered by phagocyte activation. Furthermore, these compounds inhibit the secretion of a battery of pro-inflammatory cytokines, modulate intestinal microbiota and are especially able to control the various disorders of the insulin receptor and post-receptor signaling systems. Although most of the evidence on the effects of berberine, quercetin and silymarin in modulating insulin resistance and preventing cardiovascular disease derive from experimental studies on animals, the amount of pre-clinical knowledge strongly suggests the need to investigate the therapeutic potential of these substances in human pathology.
Keywords: berberine; diabetes; flavonoids; food supplements; insulin resistance; insulin signaling; oxidative stress; quercetin; silymarin.
Conflict of interest statement
P.B. has a consultation with Vanda Omeopatici s.r.l. (Roma, Frascati), a company which produces food supplements, but that company had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. S.F. and F.A. have no potential conflicts of interest to declare.
Figures



Similar articles
-
A Descriptive Review of the Antioxidant Effects and Mechanisms of Action of Berberine and Silymarin.Molecules. 2024 Sep 26;29(19):4576. doi: 10.3390/molecules29194576. Molecules. 2024. PMID: 39407506 Free PMC article. Review.
-
Bioimpedance analysis, metabolic effects and safety of the association Berberis aristata/Bilybum marianum: a 52-week double-blind, placebo-controlled study in obese patients with type 2 diabetes.J Biol Regul Homeost Agents. 2017 Apr-Jun;31(2):495-502. J Biol Regul Homeost Agents. 2017. PMID: 28685558 Clinical Trial.
-
Silybum marianum (milk thistle) and its main constituent, silymarin, as a potential therapeutic plant in metabolic syndrome: A review.Phytother Res. 2018 Oct;32(10):1933-1949. doi: 10.1002/ptr.6153. Epub 2018 Jul 17. Phytother Res. 2018. PMID: 30015401 Review.
-
Lower glycemic indices and lipid profile among type 2 diabetes mellitus patients who received novel dose of Silybum marianum (L.) Gaertn. (silymarin) extract supplement: A Triple-blinded randomized controlled clinical trial.Phytomedicine. 2018 May 15;44:39-44. doi: 10.1016/j.phymed.2018.03.050. Epub 2018 Mar 19. Phytomedicine. 2018. PMID: 29895491 Clinical Trial.
-
Recent advances in the analysis of flavonolignans of Silybum marianum.J Pharm Biomed Anal. 2016 Oct 25;130:301-317. doi: 10.1016/j.jpba.2016.05.034. Epub 2016 May 26. J Pharm Biomed Anal. 2016. PMID: 27321822 Review.
Cited by
-
A Descriptive Review of the Antioxidant Effects and Mechanisms of Action of Berberine and Silymarin.Molecules. 2024 Sep 26;29(19):4576. doi: 10.3390/molecules29194576. Molecules. 2024. PMID: 39407506 Free PMC article. Review.
-
Insulin Resistance, a Risk Factor for Alzheimer's Disease: Pathological Mechanisms and a New Proposal for a Preventive Therapeutic Approach.Biomedicines. 2024 Aug 19;12(8):1888. doi: 10.3390/biomedicines12081888. Biomedicines. 2024. PMID: 39200352 Free PMC article. Review.
-
Silibinin's role in counteracting neuronal apoptosis and synaptic dysfunction in Alzheimer's disease models.Apoptosis. 2025 Apr;30(3-4):861-879. doi: 10.1007/s10495-024-02073-x. Epub 2025 Jan 20. Apoptosis. 2025. PMID: 39833635
-
Sitosterol-rich Digera muricata against 7-ketocholesterol and lipopolysaccharide-mediated atherogenic responses by modulating NF-ΚB/iNOS signalling pathway in macrophages.3 Biotech. 2023 Oct;13(10):331. doi: 10.1007/s13205-023-03741-6. Epub 2023 Sep 3. 3 Biotech. 2023. PMID: 37670802 Free PMC article.
-
Clinically Effective Molecules of Natural Origin for Obesity Prevention or Treatment.Int J Mol Sci. 2024 Feb 25;25(5):2671. doi: 10.3390/ijms25052671. Int J Mol Sci. 2024. PMID: 38473918 Free PMC article. Review.
References
-
- Simonetti G., Ugenti R., Casciello M., Acquaviva S., Agrimi U., Alario M., Alessandrelli M., Alfonsi V., Aloi R., Aloisi F., et al. Relazione Sullo Stato Sanitario del Paese 2012–2013. Malattie Cardio-Cerebrovascolari. Ministero della Salute-Presidenza Italiana del Consiglio EU 2014; Roma, Italy: 2014. pp. 72–76.
-
- Istituto Superiore di Sanità . Le Statistiche Delle Malattie Cardiovascolari in Europa per il 2008. Istituto Superiore di Sanità-EpiCentro; Roma, Italy: 2008.
-
- Bermudez V., Salazar J., Martinez M.S., Chavez-Castillo M., Olivar L.C., Calvo M.J., Palmar J., Bautista J., Ramos E., Cabrera M., et al. Prevalence and Associated Factors of Insulin Resistance in Adults from Maracaibo City, Venezuela. Adv. Prev. Med. 2016;2016:9405105. doi: 10.1155/2016/9405105. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical